Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山 東 威 高 集 團 醫 用 高 分 子 製 品 股 份 有 限 公 司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the "Board") of Shandong Weigao Group Medical Polymer Company Limited (the "Company") announces that Mr. Jean-Luc Butel ("Mr. Butel") has resigned as a non-executive director of the Company with effect from 7 March 2012 due to his other business commitments. Mr. Butel has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the shareholders of the Company.

The Board would like to take this opportunity to thank Mr. Butel for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that, Mr. Christopher J. O' Connell ("Mr. O'Connell") nominated by Medtronic Inc ("Medtronic"), has been appointed as a non-executive director of the Company subject to the approval by the shareholders of the Company at the upcoming annual general meeting to be held at 9:00 a.m. on Monday, 21 May 2012 or any adjournment thereof.

* *For identification purpose only*

Mr. O'Connell, aged 45, is Executive Vice President of Medtronic, Inc., and President of the Restorative Therapies Group of Medtronic. Mr. O'Connell is responsible for Medtronic's spinal/orthopedics and biologics, neuromodulation, diabetes, and surgical technologies business units globally. Mr. O'Connell provides overall strategic direction and global operational oversight for this group of related businesses, as well as leading the integration of the group's activities with the overall strategy of Medtronic.

Mr. O'Connell joined Medtronic in 1994 and has held a variety of leadership positions within the company. From 2006 to 2009, Mr. O'Connell served as Senior Vice President and President of the diabetes business, based in Northridge, California. From 2005 to 2006, he served as President of Medtronic Physio-Control, based in Redmond, Washington. Mr. O'Connell has also held key leadership positions in Medtronic's cardiac rhythm disease management business, including Vice President of Sales and Marketing, and Vice President/ General Manager of the Patient Management Business. In addition, Mr. O'Connell led key corporate functions as Vice President of Corporate Strategy, and Director of Investor Relations.

Before joining Medtronic, Mr. O' Connell worked for the corporate finance unit of Chemical Bank. Mr. O'Connell earned a bachelor's degree from Northwestern University in 1989 and a master's degree in business administration from Harvard University in 1994.

There is no service contract entered into between the Company and Mr. O' Connell, Mr. O' Connell will not receive remuneration arising from his appointment as a non-executive director of the Company. Mr. O' Connell is not entitled to any other benefits.

As of the date of this Announcement, Medtronic Holding Switzerland GmbH, a wholly owned subsidiary of Medtronic and is the substantial shareholder of the Company, holds 322,884,324 non-listed shares and 294,096,324 H shares of the Company. Saved as disclosed above, Mr. O' Connell has not previously held or currently holds any position in the Company or its subsidiaries and he does not have any relationship with any directors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules")). Mr. O' Connell has not held any directorship in other listed companies in Hong Kong or overseas during the last three years.

As at the date of this announcement, Mr. O' Connell does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other matters that are required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or any other matters in relation to the appointment of Mr. O'Connell that need to be brought to the attention of the Shareholders.

The Board would also like to express its warmest welcome to Mr. O'Connell in joining the Company.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Chen Xue Li
Chairman

Weihai, Shandong, the PRC
7 March 2012

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei *(Executive Director)*
Mr. Miao Yan Guo *(Executive Director)*
Mr. Wang Yi *(Executive Director)*
Mr. Wang Zhi Fan *(Executive Director)*
Mr. Wu Chuan Ming *(Executive Director)*
Mr. Chen Xue Li *(Non-executive Director)*
Mrs. Zhou Shu Hua *(Non-executive Director)*
Mr. Li Bing Yung *(Non-executive Director)*
Mrs. Fu Ming Zhong *(Independent non-executive Director)*
Mr. Luan Jian Ping *(Independent non-executive Director)*
Mr. Li Jia Miao *(Independent non-executive Director)*
Mr. Lo Wai Hung *(Independent non-executive Director)*